BUFFALO, N.Y. — A New York City-based biotech company is getting a boost in Buffalo as it explores the potential of its lead product – a toothpaste that helps peanut allergy sufferers.
Intrommune Therapeutics' toothpaste contains small amounts of allergens, helping patients build up a tolerance toward the goal of less severe reactions if they are exposed to peanuts.
The company has entered human trials with the support of Circuit Clinical – a startup in Buffalo that helps companies administer clinical trials – and has enrolled about eight patients toward its overall goal of 40.
